Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px
Document › Details

Santhera Pharmaceuticals. (9/3/13). "Press Release: Santhera Closes License-back Deal with Takeda for European Rights to Catena in Duchenne Muscular Dystrophy". Liestal.

Region Region Europe
Organisations Organisation Santhera Pharmaceuticals Holding AG (SIX: SANN)
  Group Santhera (Group)
  Organisation 2 Takeda Pharmaceutical Co., Ltd. (TSE: 4502)
  Group Takeda (Group)
Product Product Catena®
Person Person Meier, Thomas (Santhera 201303 CEO before CSO)
     


Santhera Pharmaceuticals (SIX: SANN) announced today that it reached an agreement with Takeda to license back previously granted European rights to Catena® (INN: idebenone) in Duchenne Muscular Dystrophy (DMD). In a back-loaded deal, Santhera regains European commercialization rights for Catena®. The drug is currently being investigated in a Phase III study in DMD conducted in Europe and in the USA.

In 2007, Takeda Pharmaceutical Company Limited (TSE: 4502, "Takeda") acquired the exclusive marketing rights in Europe and Switzerland for Catena® for the treatment of DMD. Under the agreement reached today, Santhera licenses back all such previously granted rights to increase its strategic flexibility. In return, Takeda is eligible to obtain a percentage from future licensing and/or sales income generated by Santhera in DMD. In addition, Santhera has obtained the right to cross-reference Takeda's idebenone data for regulatory use in any indication in any territory. If Santhera makes use of such cross-reference right, Takeda is eligible to obtain a percentage from future licensing and/or sales income generated by Santhera in such indications. Lastly, both companies agreed to terminate a similar agreement for Friedreich's Ataxia signed in 2005 and Santhera's previously disclosed contingent liability of EUR 1 million payable to Takeda has been waived. Takeda is eligible to receive Euro 1 million as a percentage from future income generated by Santhera to offset this waiver.

"The agreement we reached today with Takeda clearly increases our strategic flexibility. Potential licensees interested in Catena® in DMD can now be offered global rights to this program", commented Thomas Meier, CEO of Santhera. "The ongoing DELOS study has recently passed a futility analysis and we expect to report top-line data from the first cohort of patients in this study in the second quarter of 2014. Today's agreement with Takeda also grants us right of cross-reference to certain data which may be needed for any regulatory filings for indications currently being developed or which may be developed in the future."


About Duchenne Muscular Dystrophy and the DELOS Phase III trial

Duchenne Muscular Dystrophy is one of the most common and devastating type of muscular degeneration and results in rapidly progressive muscle weakness. It is a genetic, degenerative disease that is inherited in an X-linked recessive mode with an incidence of approximately 1 in 3,500 live born males worldwide. DMD is characterized by a complete loss of the protein dystrophin, leading to cell damage, impaired calcium homeostasis, elevated oxidative stress and reduced energy production in muscle cells. This results in progressive muscle weakness and wasting and early morbidity due to respiratory failure.

DELOS (DuchEnne Muscular Dystrophy Long-term IdebenOne Study) is a Phase III randomized, placebo-controlled double-blind study in patients aged 10-18 years with DMD of any mutational etiolology, ambulatory or non-ambulatory, recruited in Europe and in North America. The study, previously agreed with both the EMA and the FDA, is designed to assess the efficacy of orally administered Catena® (900 mg/day) in improving or delaying the loss of respiratory function in Duchenne patients compared to placebo. The study plans to sequentially enroll two cohorts of patients, 60 corticosteroid non-using and 200 corticosteroid using patients, to allow these sub-groups to be independently powered for efficacy and analyzed separately in the final primary endpoint analysis. As was agreed with both the US and European regulatory agencies, DELOS is intended to provide pivotal efficacy data for regulatory filings for Catena® in the treatment of patients with DMD in these territories.

Recently, the independent Data Safety Monitoring Board for DELOS informed Santhera that the study has a reasonable chance of achieving its primary endpoint for improving or delaying the loss of respiratory function in Duchenne patients not using corticosteroids and since no safety issues were detected, recommended that the study should continue as planned.

Idebenone is a synthetic short-chain benzoquinone and a cofactor for the enzyme NAD(P)H:quinone oxidoreductase (NQO1) capable of transferring electrons directly onto complex III of the mitochondrial electron transport chain, thereby capable of restoring cellular energy levels. Santhera develops Catena®/Raxone® as treatment for patients with DMD, Leber's Hereditary Optic Neuropathy (LHON), and primary progressive multiple sclerosis (ppMS).

* * *

About Santhera

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases, areas of high unmet medical need with no current therapies. For further information, please visit www.santhera.com.

Catena® and Raxone® are trademarks of Santhera Pharmaceuticals.

For further information, contact
Thomas Meier, Chief Executive Officer
Phone: +41 61 906 89 64
thomas.meier@santhera.com


Disclaimer / Forward-looking statements

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Santhera (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px




» top